Cynvenio Biosystems Co-Founder & Chairman Honored by the Scholarship Foundation of Santa Barbara

WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)– Cynvenio Biosystems, Inc., a developer of rare cell isolation systems for biomedical research in circulating tumor cells, personalized medicine and the molecular diagnostics of cancer, announced today that Fred Gluck, its co-Founder and Chairman of the Board, will be the recipient of the 2012 South Coast Pioneer Award. The Scholarship Foundation of Santa Barbara will honor Fred Gluck and four other outstanding companies and individuals at the South Coast Business & Technology Awards dinner on June 14, 2012 at Fess Parkers Doubletree Resort in Santa Barbara, California. Now in its 18th year, the South Coast Business & Technology Awards was designed to honor individuals and organizations who have demonstrated an extraordinary commitment to helping the South Coast of Santa Barbara County remain economically vital Continue reading

Read the Rest...

Ultrasensitive biosensor promising for medical diagnostics

This graphic depicts a new ultrasensitive biosensor that could open up new opportunities for early detection of cancer and “personalized medicine” tailored to the specific biochemistry of individual patients. The device, called a Flexure-FET biosensor, could be several hundred times more sensitive than other biosensors. (Purdue University image) (Phys.org) — Researchers have created an ultrasensitive biosensor that could open up new opportunities for early detection of cancer and “personalized medicine” tailored to the specific biochemistry of individual patients. Continue reading

Read the Rest...

A new dimension to DNA and personalized medicine of the future

(Phys.org) — By investigating the existence of an unusual four-stranded structure of DNA in human cells, scientists have opened the door to novel cancer therapeutics and a new era for personalised medicine. Continue reading

Read the Rest...

New Equation in Prostate Cancer Diagnosis Yields Best Answer Yet

NEW YORK, NY–(Marketwire -05/15/12)- World-renowned prostate surgeon, Dr. David Samadi, may soon have the equation he needs to strengthen his approach to personalized medicine and prostate cancer treatment. Researchers at the University of Pittsburgh School of Medicine developed a new prostate cancer diagnostic formula to accurately predict the lifecycle of a man’s prostate cancer Continue reading

Read the Rest...

Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through 'Precision Medicine'

Newswise New Brunswick, N.J., May 15, 2012 With recent advancements in technology and biomedical informatics, a more personalized approach to prescribing cancer treatment and developing these therapies is preferred over one-size-fits-all methods. The Cancer Institute of New Jersey (CINJ) has been on the cutting-edge of this movement and is now launching a more concrete effort that is poised to change the way that molecular and genetic information is being used to diagnose and treat cancer an initiative known as precision medicine also known to many as personalized medicine Continue reading

Read the Rest...

Pfizer Provides Topline Results From Phase 3 Study Of Torisel® As Second-Line Treatment In Advanced Renal Cell …

NEW YORK–(BUSINESS WIRE)– Pfizer Inc announced today that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL (temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib. Although PFS was numerically higher in patients treated with temsirolimus, the difference was not statistically significant. Overall survival, a secondary endpoint in the study, showed statistical significance favoring patients randomized to the sorafenib arm. Continue reading

Read the Rest...

TiGenix Reports Business & Financial Results for the First Quarter 2012

LEUVEN, BELGIUM–(Marketwire -05/15/12)- TiGenix NV (TIG) a leader in the field of cell therapy, today gave a business update and announced the financial results for the first quarter ending March 31, 2012. Business highlights Financial highlights “In the first quarter 2012 we continued to aggressively push our commercial efforts forward,” said Eduardo Bravo, CEO of TiGenix Continue reading

Read the Rest...

Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant

Public release date: 15-May-2012 [ | E-mail | Share ] Contact: Elisa Williams willieli@ohsu.edu 503-494-4530 Oregon Health & Science University PORTLAND, Ore. Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science University Knight Cancer Institute. The study, published in the New England Journal of Medicine, found a 63 percent reduction in the risk of progressive myeloma or death for the stem cell transplant patients that were treated with lenalidomide maintenance therapy Continue reading

Read the Rest...

Fibrocell Science, Inc. Announces Exclusive License Agreement with UCLA on Dermal Cell Research to Advance the …

EXTON, Pa.–(BUSINESS WIRE)– Fibrocell Science, Inc. Continue reading

Read the Rest...

Gamida Cell Closes $10 Million E Financing Round Earmarked to Support the Global Commercialization of the Company’s …

JERUSALEM–(BUSINESS WIRE)– Gamida Cell announced today that it has closed an internal E financing round of $10 million. All major shareholders participated. The financing will be used to support the global commercialization of the companys lead cell therapy product, StemEx, in development as an alternative therapeutic treatment for patients with blood cancers, such as leukemia and lymphoma, who can be cured by bone marrow transplantation but do not have a matched bone marrow donor. Continue reading

Read the Rest...

Genetic test can accurately predict spread of eye cancer

Researchers at Washington University School of Medicine in St. Louis have developed a genetic test that can accurately predict whether the most common form of eye cancer will spread to other parts of the body, particularly the liver. In 459 patients with ocular melanoma at 12 centers in the United States and Canada, the researchers found the test could successfully classify tumors more than 97 percent of the time Continue reading

Read the Rest...

Schizophrenia’s core genetic features proposed

Researchers may be closing in on diseases inherited component Web edition : Tuesday, May 15th, 2012 Schizophrenias elusive genetic roots may finally be within grasp. A new, wide-ranging effort has uncovered a set of DNA signatures that are shared by people with the disease consistently enough that the set can be used to reliably predict whether someone has the disease. Continue reading

Read the Rest...

Genetic test identifies eye cancer tumors likely to spread

Public release date: 14-May-2012 [ | E-mail | Share ] Contact: Jim Dryden jdryden@wustl.edu 314-286-0110 Washington University School of Medicine Researchers at Washington University School of Medicine in St. Louis have developed a genetic test that can accurately predict whether the most common form of eye cancer will spread to other parts of the body, particularly the liver. In 459 patients with ocular melanoma at 12 centers in the United States and Canada, the researchers found the test could successfully classify tumors more than 97 percent of the time. Continue reading

Read the Rest...

Given number of inheritors, donor sperm carries risk of genetic harm

In households across the country, children conceived with donated sperm are struggling with serious genetic conditions inherited from men they have never met: heart defects, spinal muscular atrophy, neurofibromatosis type 1 and fragile-X syndrome the most common form of mental retardation in boys and others. Donated eggs pose a risk as well, but the threat of genetic harm from sperm donation is arguably much greater. Sperm donors are no more likely to carry genetic diseases than anybody else, but they can father a far greater number of children: 50, 100 or even 150, each a potential inheritor of flawed genes. Continue reading

Read the Rest...

Abraham’s genetic threads | Gene Expression

Every few days my Google Alerts have been dropping in my inbox reviews of Harry Osters Legacy: A Genetic History of the Jewish People. Continue reading

Read the Rest...

A Little More Education, a Little Longer Life?

MONDAY, May 14 (HealthDay News) — It's graduation season, and new research offers yet another reason to congratulate someone who has completed at least nine years of education: They're likely to live longer. Continue reading

Read the Rest...

Health Buzz: Home HIV Test Backed By FDA Panel

FDA Panel Supports Rapid, At-Home HIV Test Home HIV tests should be sold in retail stores, a U.S. Food and Drug Administration advisory panel urged Tuesday. If approved by the FDA, a mouth-swab test made by OraSure Technologies Inc.and sold commercially to health professionalswould become available over the counter. Continue reading

Read the Rest...

Death risk for marathoners remains low during or soon after race

Public release date: 15-May-2012 [ | E-mail | Share ] Contact: Stephanie Desmon sdesmon1@jhmi.edu 410-955-8665 Johns Hopkins Medical Institutions Even though hundreds of thousands more people finished grueling 26.2 mile marathons in the United States in 2009 compared to a decade earlier, a runner’s risk of dying during or soon after the race has remained very low about .75 per 100,000, new Johns Hopkins research suggests. Men, however, were twice as likely to die as women. “It’s very dramatic when someone dies on the course, but it’s not common,” says Julius Cuong Pham, M.D., Ph.D., an associate professor of emergency medicine and anesthesiology and critical care medicine at the Johns Hopkins University School of Medicine, and leader of the study published online in The American Journal of Sports Medicine Continue reading

Read the Rest...

What Role Do Drugs Play in Determining Longevity?

If you're a typical American, chances are about 50-50 that you take at least one prescription drug–and if you're upwards of 60, the odds are nearly 2 in 5 that you take five drugs or more. Some may be lifesaving, especially for those with potentially deadly chronic conditions like diabetes or high blood pressure. But how many drugs in those mountains of pills add years to the lives of people … Continue reading

Read the Rest...

First gene therapy successful against aging-associated decline: Mouse lifespan extended up to 24% with a single …

ScienceDaily (May 14, 2012) A new study consisting of inducing cells to express telomerase, the enzyme which — metaphorically — slows down the biological clock — was successful. Continue reading

Read the Rest...

Gene therapy may extend life: Study

The therapy could be used in anti-aging therapy in humans down the road, but the researchers say in the short term it could possibly be used to treat health problems such as tissue-related ailments. Continue reading

Read the Rest...

You can help 'vibrant young woman' in Comox Valley to battle cystic fibrosis

Comox Valley residents are invited to help local youngster Amethyst Hamersley battle cystic fibrosis. Continue reading

Read the Rest...

Cyclist plans Cystic Fibrosis charity ride at Maritime Gig

Gig Harbor resident Eric McGinnis is planning to ride a stationary bike at the Maritime Gig Festival for 48 continuous hours and hopes to ride more than 500 miles to raise awareness for Cystic Fibrosis. He gets his inspiration from his young friend Lily Paulson, also from Gig Harbor, who, at 8 years old, has faced the challenges of living with Cystic Fibrosis since the day she was born. From a booth at Skansie Brothers Park, McGinnis will spin the wheels on the bike beginning at 4 p.m. Continue reading

Read the Rest...